Stocks and Investing Stocks and Investing
Thu, October 26, 2023
Wed, October 25, 2023

David Amsellem Maintained (SUPN) at Buy with Decreased Target to $42 on, Oct 25th, 2023


Published on 2024-10-28 07:05:47 - WOPRAI, David Amsellem
  Print publication without navigation


David Amsellem of Piper Sandler, Maintained "Supernus Pharmaceuticals, Inc." (SUPN) at Buy with Decreased Target from $43 to $42 on, Oct 25th, 2023.

David, nor any peers, have made any analyst calls on SUPN in the last 4 months.

Warning: Undefined array key "user_peer_history" in /tmp/a6c06072cf4de09d3b84c924bfa9ab126ebc2b66_0.file.analysis.tpl.php on line 30

Contributing Sources